AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32658497 — intervention group
Group type: COMPARATOR
Intervention: Migraine education (ME)
Number of subjects: 110
Study 32658497 — intervention group
Group type: EXPERIMENTAL
Intervention: Both BWL and ME
Number of subjects: 110
Study 35887855 — intervention group
Group type: COMPARATOR
Intervention: BoNT injections alone
Number of subjects: 0
Study 35887855 — intervention group
Group type: EXPERIMENTAL
Intervention: BoNT injections with OA therapy
Number of subjects: 0
Study 36424485 — intervention group
Group type: EXPERIMENTAL
Intervention: MARF + PRF membrane
Number of subjects: 10
Study 36424485 — intervention group
Group type: COMPARATOR
Intervention: MARF only
Number of subjects: 10
Study 33648546 — intervention group
Group type: EXPERIMENTAL
Intervention: EPA and DHA (600 mg EPA and 260 mg DHA per day)
Number of subjects: 22
Study 33648546 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 22
Study 34794973 — intervention group
Group type: EXPERIMENTAL
Intervention: CGM + DSS
Number of subjects: 80
Study 34794973 — intervention group
Group type: COMPARATOR
Intervention: CGM
Number of subjects: 80
Study 34794973 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (CGM + DSS and CGM)
Number of subjects: 80
Study 34794973 — intervention group
Group type: EXPERIMENTAL
Intervention: DSS
Number of subjects: 80
Study 34794973 — intervention group
Group type: EXPERIMENTAL
Intervention: Active DSS users
Number of subjects: 80
Study 33893213 — intervention group
Group type: EXPERIMENTAL
Intervention: I-PASS handoff bundle (Spanish version) including written and verbal handoff, teamwork training, advertising campaign, simulation exercises, observation, and standardized feedback.
Number of subjects: 1465
Study 33893213 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 1465
Study 33893213 — intervention group
Group type: EXPERIMENTAL
Intervention: I-PASS handoff bundle (Spanish version)
Number of subjects: 1465
Study 32915891 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 minutes of additional low intensity exercise (n = 47)
Number of subjects: 92
Study 32915891 — intervention group
Group type: COMPARATOR
Intervention: Stopping at peak exertion (n = 45)
Number of subjects: 92
Study 35471896 — intervention group
Group type: EXPERIMENTAL
Intervention: Text intervention
Number of subjects: 0
Study 35471896 — intervention group
Group type: EXPERIMENTAL
Intervention: Video intervention
Number of subjects: 0
Study 35471896 — intervention group
Group type: COMPARATOR
Intervention: Comparison of text and video interventions
Number of subjects: 0
Study 33847344 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 g cod fillet twice weekly for 16 weeks
Number of subjects: 133
Study 33417682 — intervention group
Group type: EXPERIMENTAL
Intervention: Canakinumab (anti-inflammatory therapy)
Number of subjects: 60087
Study 33417682 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60087
Study 33417682 — intervention group
Group type: COMPARATOR
Intervention: Rosuvastatin
Number of subjects: 60087
Study 33417682 — intervention group
Group type: COMPARATOR
Intervention: Bococizumab
Number of subjects: 60087
Study 33417682 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate
Number of subjects: 60087
Study 33417682 — intervention group
Group type: EXPERIMENTAL
Intervention: NLR quartiles
Number of subjects: 60087
Study 36235775 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Fat Diet (HFD)
Number of subjects: 15
Study 36235775 — intervention group
Group type: COMPARATOR
Intervention: High-Carbohydrate Diet (HCD)
Number of subjects: 15
Study 33851734 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness and acceptance-based treatment (MABT)
Number of subjects: 44
Study 33851734 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 44
Study 36179950 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral factor Xa inhibitors (apixaban, betrixaban, rivaroxaban)
Number of subjects: 97578
Study 36179950 — intervention group
Group type: COMPARATOR
Intervention: Rivaroxaban 5 mg twice daily
Number of subjects: 97578
Study 36179950 — intervention group
Group type: COMPARATOR
Intervention: Oral factor Xa inhibitors
Number of subjects: 97578
Study 33410564 — intervention group
Group type: EXPERIMENTAL
Intervention: Fully covered self-expandable metal stents (FCSEMS)
Number of subjects: 22
Study 33410564 — intervention group
Group type: COMPARATOR
Intervention: Plastic stents (PS)
Number of subjects: 22
Study 35816916 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral prevention program (matched)
Number of subjects: 98
Study 35816916 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal prevention program (mismatched)
Number of subjects: 98
Study 35816916 — intervention group
Group type: COMPARATOR
Intervention: Control group (equivalent rates of anxiety disorders)
Number of subjects: 98
Study 34283917 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent psychological intervention administered through an interactive multimedia online videogame with a complementary smartphone app
Number of subjects: 25
Study 33085033 — intervention group
Group type: EXPERIMENTAL
Intervention: JNJ‐55920839 10 mg/kg IV 6 times biweekly in subjects with SLE
Number of subjects: 74
Study 33085033 — intervention group
Group type: COMPARATOR
Intervention: JNJ‐55920839 (various doses between 0.3 and 15 mg/kg IV or 1 mg/kg SC) in healthy subjects
Number of subjects: 74
Study 33085033 — intervention group
Group type: EXPERIMENTAL
Intervention: JNJ‐55920839 (10 mg/kg IV) in subjects with SLE
Number of subjects: 74
Study 33085033 — intervention group
Group type: COMPARATOR
Intervention: JNJ‐55920839 (various doses) in healthy subjects
Number of subjects: 74
Study 35113224 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranking-down (RD) group starting with a very strong corticosteroid, ranked down every 2 weeks unless FAfE exacerbated
Number of subjects: 0
Study 35113224 — intervention group
Group type: COMPARATOR
Intervention: Ranking-up (RU) group starting with a weak corticosteroid, ranked up at exacerbation
Number of subjects: 0
Study 34486662 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise (3 times a week for 8 weeks)
Number of subjects: 19
Study 34849546 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (2000 IU/d; n=499)
Number of subjects: 666
Study 34849546 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=167)
Number of subjects: 666
Study 34849546 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (2000 IU/d) with baseline 25(OH)D <20 ng/mL
Number of subjects: 666
Study 34849546 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (2000 IU/d) with baseline 25(OH)D of 20-30 ng/mL
Number of subjects: 666
Study 34849546 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (2000 IU/d)
Number of subjects: 666
Study 34849546 — intervention group
Group type: COMPARATOR
Intervention: Vitamin D3 (2000 IU/d) and Placebo
Number of subjects: 666
Study 34334720 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO hydrogel (90 g·h‐1 of 2:1 glucose‐fructose)
Number of subjects: 11
Study 34334720 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard CHO solution (nonhydrogel)
Number of subjects: 11
Study 34334720 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO hydrogel
Number of subjects: 11
Study 34334720 — intervention group
Group type: COMPARATOR
Intervention: CHO conditions (hydrogel and nonhydrogel)
Number of subjects: 11
Study 34139464 — intervention group
Group type: EXPERIMENTAL
Intervention: modified lower-protein (mLP) infant formula (1.7 g protein/100 kcal)
Number of subjects: 143
Study 34139464 — intervention group
Group type: COMPARATOR
Intervention: control formula (CTRL) (2.1 g protein/100 kcal)
Number of subjects: 143
Study 34139464 — intervention group
Group type: EXPERIMENTAL
Intervention: breast-fed (BF) group
Number of subjects: 143
Study 33727160 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic pain
Number of subjects: 0
Study 33727160 — intervention group
Group type: COMPARATOR
Intervention: Control task
Number of subjects: 0
Study 32448187 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-partnered delirium prevention, detection, and management
Number of subjects: 198
Study 32448187 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 198
Study 35733283 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous acetazolamide (500 mg)
Number of subjects: 519
Study 35733283 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 519
Study 32424868 — intervention group
Group type: EXPERIMENTAL
Intervention: Split high-dose sennoside solutions (1000 mg)
Number of subjects: 474
Study 32424868 — intervention group
Group type: COMPARATOR
Intervention: Split-dose polyethylene glycol (4 L)
Number of subjects: 474
Study 35102477 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini-implant assisted rapid palatal expansion (MARPE)
Number of subjects: 32
Study 35102477 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 32
Study 35986649 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral nutrition supplements (ONSs) (400 kcal/day) and family-centered nutrition education (once every 2 weeks)
Number of subjects: 201
Study 35986649 — intervention group
Group type: COMPARATOR
Intervention: Family-centered nutrition education (control group)
Number of subjects: 201
Study 35986649 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral nutrition supplements (ONSs) and family-centered nutrition education
Number of subjects: 201
Study 34964778 — intervention group
Group type: EXPERIMENTAL
Intervention: ERAS nursing combined with rehabilitation training
Number of subjects: 60
Study 34964778 — intervention group
Group type: COMPARATOR
Intervention: Routine nursing
Number of subjects: 60
Study 35667837 — intervention group
Group type: EXPERIMENTAL
Intervention: Ponesimod 20 mg
Number of subjects: 464
Study 35667837 — intervention group
Group type: COMPARATOR
Intervention: Ponesimod 10 mg
Number of subjects: 464
Study 35667837 — intervention group
Group type: COMPARATOR
Intervention: Ponesimod 40 mg
Number of subjects: 464
Study 35667837 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 464
Study 36088283 — intervention group
Group type: EXPERIMENTAL
Intervention: Trunk-strengthening exercise group
Number of subjects: 64
Study 36088283 — intervention group
Group type: COMPARATOR
Intervention: Walking-balance exercise group
Number of subjects: 64
Study 33891597 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted client communication (TCC) via SMS
Number of subjects: 454
Study 33891597 — intervention group
Group type: COMPARATOR
Intervention: No TCC (control)
Number of subjects: 454
Study 34128826 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 7000 IU/week
Number of subjects: 192
Study 34128826 — intervention group
Group type: COMPARATOR
Intervention: Vitamin D3 2800 IU/week
Number of subjects: 192
Study 35322798 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Standardized Patients (VSPs)
Number of subjects: 66
Study 35322798 — intervention group
Group type: COMPARATOR
Intervention: Standardized Patients (SPs)
Number of subjects: 66
Study 35322798 — intervention group
Group type: EXPERIMENTAL
Intervention: High Value Care (HVC) didactics
Number of subjects: 66
Study 32530472 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (n=132)
Number of subjects: 269
Study 32530472 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=137)
Number of subjects: 269
Study 34472598 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow breathing exercise (SBE) performed at home, 30 minutes daily for 12 weeks
Number of subjects: 78
Study 34472598 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving routine post-PCI care only
Number of subjects: 78
Study 34162298 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) 100/62.5/25mcg
Number of subjects: 229
Study 34162298 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) 200/62.5/25mcg
Number of subjects: 229
Study 34162298 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone furoate/vilanterol (FF/VI)
Number of subjects: 229
Study 34162298 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI)
Number of subjects: 229
Study 33956209 — intervention group
Group type: EXPERIMENTAL
Intervention: Loop diuretic usage > 40 mg furosemide-equivalent dose
Number of subjects: 0
Study 33956209 — intervention group
Group type: EXPERIMENTAL
Intervention: Loop diuretic usage 1-40 mg furosemide-equivalent dose
Number of subjects: 0
Study 33956209 — intervention group
Group type: COMPARATOR
Intervention: No baseline loop diuretic usage
Number of subjects: 0
Study 33956209 — intervention group
Group type: COMPARATOR
Intervention: History of hospitalization and/or elevated natriuretic peptides
Number of subjects: 0
Study 35451469 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium (3.2 g daily for 72 hours preoperatively and 1.6 g on the day of surgery)
Number of subjects: 200
Study 35451469 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 35451469 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium
Number of subjects: 200
Study 34081085 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk-reducing salpingo-oophorectomy (RRSO) without hormone replacement therapy
Number of subjects: 577
Study 34081085 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk-reducing salpingo-oophorectomy (RRSO) with hormone replacement therapy
Number of subjects: 577
Study 34081085 — intervention group
Group type: COMPARATOR
Intervention: Risk-reducing salpingectomy (RRS)
Number of subjects: 577
Study 32522273 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard dose Lingguizhugan decoction (SLGD)
Number of subjects: 243
Study 32522273 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose Lingguizhugan decoction (LLGD)
Number of subjects: 243
Study 32522273 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 243
Study 35051154 — intervention group
Group type: EXPERIMENTAL
Intervention: PE RA-TLIF
Number of subjects: 58
Study 35051154 — intervention group
Group type: COMPARATOR
Intervention: MIS-TLIF
Number of subjects: 58
Study 34693689 — intervention group
Group type: EXPERIMENTAL
Intervention: Recognan (citicoline), 500 mg daily for 30 days
Number of subjects: 54
Study 34693689 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 54
Study 32784231 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose lidocaine (CIESI-L)
Number of subjects: 120
Study 32784231 — intervention group
Group type: COMPARATOR
Intervention: Saline (CIESI-S)
Number of subjects: 120
Study 33370208 — intervention group
Group type: EXPERIMENTAL
Intervention: Trauma-Focused Cognitive-Behavioral Therapy (TF-CBT)
Number of subjects: 57
Study 32103772 — intervention group
Group type: EXPERIMENTAL
Intervention: Team sport condition
Number of subjects: 161
Study 32103772 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual sport condition
Number of subjects: 161
Study 32103772 — intervention group
Group type: COMPARATOR
Intervention: Personal time control condition
Number of subjects: 161
Study 36464137 — intervention group
Group type: EXPERIMENTAL
Intervention: Active TBS
Number of subjects: 28
Study 36464137 — intervention group
Group type: COMPARATOR
Intervention: Sham TBS
Number of subjects: 28
Study 32308168 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenting-focused preventive intervention (11-session program)
Number of subjects: 240
Study 32308168 — intervention group
Group type: COMPARATOR
Intervention: Literature control condition
Number of subjects: 240
Study 32187115 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabis use (including blunts)
Number of subjects: 262
Study 32187115 — intervention group
Group type: EXPERIMENTAL
Intervention: Polytobacco product use (not including blunts)
Number of subjects: 262
Study 32187115 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressive symptoms
Number of subjects: 262
Study 32187115 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger age
Number of subjects: 262
Study 35223106 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose tranexamic acid (TXA)
Number of subjects: 204
Study 35223106 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline infusion)
Number of subjects: 204
Study 34660913 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Number of subjects: 12
Study 36437161 — intervention group
Group type: EXPERIMENTAL
Intervention: ECAP-CL SCS
Number of subjects: 134
Study 33978745 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronate infusion after denosumab treatment (≤ 6 Group)
Number of subjects: 47
Study 33978745 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronate infusion after denosumab treatment (> 6 Group)
Number of subjects: 47
Study 33978745 — intervention group
Group type: COMPARATOR
Intervention: Comparison of LS-BMD changes between groups
Number of subjects: 47
Study 33978745 — intervention group
Group type: COMPARATOR
Intervention: Correlation of denosumab treatment duration with LS-BMD change
Number of subjects: 47
Study 32348248 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil SE Bond 2 with light curing of both adhesive and cement
Number of subjects: 3
Study 32348248 — intervention group
Group type: EXPERIMENTAL
Intervention: ExciTE F DSC with various light-curing and self-curing combinations
Number of subjects: 3
Study 32348248 — intervention group
Group type: EXPERIMENTAL
Intervention: Universal Primer with various light-curing and self-curing combinations
Number of subjects: 3
Study 32348248 — intervention group
Group type: EXPERIMENTAL
Intervention: All 3 adhesives with no light curing of adhesive or cement
Number of subjects: 3
Study 34455443 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital therapeutics group (HERB system + standard lifestyle modification)
Number of subjects: 390
Study 34455443 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard lifestyle modification alone)
Number of subjects: 390
Study 32958075 — intervention group
Group type: EXPERIMENTAL
Intervention: Fremanezumab quarterly (675 mg)
Number of subjects: 1130
Study 32958075 — intervention group
Group type: EXPERIMENTAL
Intervention: Fremanezumab monthly (675 mg)
Number of subjects: 1130
Study 35488225 — intervention group
Group type: EXPERIMENTAL
Intervention: Vapocoolant spray
Number of subjects: 36
Study 35488225 — intervention group
Group type: EXPERIMENTAL
Intervention: Music
Number of subjects: 36
Study 35488225 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 36
Study 33477404 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocotrienol-rich vitamin E (Tocovid SupraBioTM; Hovid Berhad, Ipoh, Malaysia) 400 mg daily
Number of subjects: 59
Study 33477404 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 34120417 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% nepafenac eye drops 4 times/day for 4 weeks
Number of subjects: 200
Study 34120417 — intervention group
Group type: COMPARATOR
Intervention: 1% prednisolone acetate eye drops in tapering doses for 4 weeks
Number of subjects: 200
Study 34120417 — intervention group
Group type: COMPARATOR
Intervention: Both groups received moxifloxacin 0.5% eye drops 4 times/day for 2 weeks
Number of subjects: 200
Study 32610257 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C (1000 mg/d)
Number of subjects: 14
Study 32610257 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 35835337 — intervention group
Group type: EXPERIMENTAL
Intervention: Tube shunt (350‐mm2 Baerveldt glaucoma implant)
Number of subjects: 242
Study 35835337 — intervention group
Group type: COMPARATOR
Intervention: Trabeculectomy with mitomycin C (MMC, 0.4 mg/ml for 2 minutes)
Number of subjects: 242
Study 35835337 — intervention group
Group type: EXPERIMENTAL
Intervention: Tube shunt
Number of subjects: 242
Study 35835337 — intervention group
Group type: COMPARATOR
Intervention: Trabeculectomy
Number of subjects: 242
Study 33834971 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal-oriented fluid resuscitation group
Number of subjects: 60
Study 33834971 — intervention group
Group type: COMPARATOR
Intervention: Routine fluid replacement group
Number of subjects: 60
Study 36460983 — intervention group
Group type: EXPERIMENTAL
Intervention: eptinezumab 100 mg
Number of subjects: 890
Study 36460983 — intervention group
Group type: EXPERIMENTAL
Intervention: eptinezumab 300 mg
Number of subjects: 890
Study 36460983 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 890
Study 33646129 — intervention group
Group type: EXPERIMENTAL
Intervention: Jaspr Health app (n=14)
Number of subjects: 31
Study 33646129 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (control; n=17)
Number of subjects: 31
Study 35544780 — intervention group
Group type: EXPERIMENTAL
Intervention: Silver-containing hydrofiber dressing (n = 16), not changed for 5 days after application.
Number of subjects: 32
Study 35544780 — intervention group
Group type: COMPARATOR
Intervention: Standard sterile gauze dressing (control group, n = 16), changed after 24 to 48 hours and replaced daily for 5 days.
Number of subjects: 32
Study 32979635 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioresorbable scaffold (BRS)
Number of subjects: 56
Study 32979635 — intervention group
Group type: COMPARATOR
Intervention: Metallic drug-eluting stent (DES)
Number of subjects: 56
Study 35717049 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone position, 5 fractions
Number of subjects: 57
Study 35717049 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone position
Number of subjects: 57
Study 35717049 — intervention group
Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 57
Study 35717049 — intervention group
Group type: COMPARATOR
Intervention: Supine position, 15 fractions
Number of subjects: 57
Study 33081783 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerometer variables measured out-of-clinic
Number of subjects: 0
Study 33081783 — intervention group
Group type: EXPERIMENTAL
Intervention: Compensatory movement score derived from video analysis of the Action Research Arm Test (ARAT)
Number of subjects: 0
Study 33081783 — intervention group
Group type: EXPERIMENTAL
Intervention: Variables quantifying time, magnitude, and variability of upper limb movement out-of-clinic
Number of subjects: 0
Study 33081783 — intervention group
Group type: COMPARATOR
Intervention: Accelerometer variables measured in-clinic
Number of subjects: 0
Study 36115789 — intervention group
Group type: EXPERIMENTAL
Intervention: Helfer skin tap technique (HSTT)
Number of subjects: 60